Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT05351593Phase 2Recruiting
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in central nervous system lymphoma. Started Jun 2022; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT05351593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351593.